Dravet syndrome is a terrible disease generally caused by mutations of the SCN1A gene. Recently others genes such as STXBP1 have been involved in the pathogenesis of the disease. The STXBP1 mutation in patients with Dravet Syndrome may additionally causes several parkinsonian features usually attributed to carriers of the SCN1A mutation. Management continues to be difficult; that is why Cannabidiol emerged as valid option for treatment of this condition.
June 22, 2018
March 2, 2021
Patient, Caregiver, and Healthcare Professional Perspectives on Seizure Control and Treatment Goals
Differing perspectives on seizure freedom, seizure control, communication priorities, and treatment goals provide opportunities to improve patient care and outcomes through more effective two-way communication and alignment of goals.